The group's principal activity is to develop an innovative antibody-driven drug on two technology platforms, SuperAntibody and TransMAbs, which improve the potency of existing antibody products and create a novel class of antibody based drugs which penetrate into cells. Antibodies are produced naturally within the body and attack (bind with) diseased cells and either weaken or destroy them, allowing a person to recover from an infection. Monoclonal Antibody technology allows one to isolate and expand individual antibodies for the treatment of numerous diseases, including cancer. Monoclonal Antibodies display qualities unlike any other drug yet discovered in that they are very specific and relatively non-toxic.
